Nomenclature: NOD.Cg-Prkdc^scid Il2rg^tm1Sug Tg(CMV-IL6)1-1Jic/JicTac

The NeoThy™ Human Immune Engraftment Platform is designed to deliver physiologic human adaptive immune function in immunodeficient mice. The platform integrates engrafted neonatal human thymic tissue fragments with cord blood–derived CD34⁺ hematopoietic stem cells (HSCs) to support human T cell development within a human thymic microenvironment and human leukocyte antigen (HLA) context.

Following implantation, thymic fragments (representing medulla and/or cortex regions with human thymic epithelial cells) vascularize and establish a functional thymic microenvironment in vivo. Human T cells undergo HLA-restricted positive and negative selection within this human thymic microenvironment, enabling peripheral immune reconstitution with functionally mature human T and B cell compartments.

Humanized mice generated using the NeoThy™ Platform demonstrate robust multilineage human immune cell engraftment and organized antigen recognition consistent with human adaptive immune biology.

• The hIL-6 huNOG mouse is a HIS mouse made by engrafting hematopoietic stem cells (HSCs) in the hIL-6 NOG strain.
• Made to order, with typical lead time of 20 weeks from order to delivery.
• Minimum purchase required. Human lymphocytes are present in peripheral blood, bone marrow and spleen.
• hIL-6 huNOG mice are a suitable control for NeoThy(TM) hIL-6 huNOG mice.
• Humanized immune system mice require special housing and husbandry. We recommend reviewing the the comprehensive document Taconic's Humanized Immune System Models: Licensing, Care & Resources and the Video: Care of HIS mice for experimental success prior to ordering.

IL-6 NOG Characteristics:

• Super immunodeficient NOG mouse expressing human IL-6 cytokine
• Enhanced expansion of human monocytes following human HSC engraftment
• May be useful for study of tumor-infiltrating macrophages
• May be suitable host for hIL-6 dependent multiple myeloma (MM) patient derived xenograft (PDX) and tumor samples.
• Applications in research involving cancer, immunology, regenerative medicine and human immune system engraftment

Orders by weight: Taconic cannot accept orders by weight for this model. Please note that shipments may contain animals with a larger weight variation.

Origin

The CIEA NOG mouse® was developed by Mamoru Ito of the Central Institute for Experimental Animals (CIEA) in Japan. The Prkdc scid mutation was identified by Mel Bosma of the Fox Chase Cancer Center in a C.B-17 congenic mouse population. This mutation was backcrossed onto the NOD/ShiJic strain at CIEA for at least eight generations. The Il2rg targeted mutation was developed by Dr. Kazuo Sugamura of Tohoku University by targeting the gene in ES cells derived from a 129 strain. Portions of exons 7 and 8 were replaced with a neo cassette. Targeted ES cells were injected into C57BL/6 blastocysts. Resultant chimeras were backcrossed onto the C57BL/6JJic background for at least eight generations. The CIEA NOG mouse® was developed by backcrossing the C57BL/6JJic-Il2rg line to the NOD/ShiJic-Prkdc scid line for a total of eight generations. The linearized hIL-6 transgene was injected into zygotes from NOD/Shi-IL2rg females x NOD/Shi-IL2rg males.  The transgenic hIL-6 NOD/Shi-IL2rg mouse was crossed onto the NOG background to introduce the Prkdc scid mutation.  The mice were backcrossed onto the NOG background three times. Taconic received stock in 2014, and the line was derived through embryo transfer.

The NeoThy™ Human Immune Engraftment Platform was developed by Matthew Brown of University of Wisconsin- Madison. NeoThy™ is a trademark of the Wisconsin Alumni Research Foundation. The NeoThy™ Human Immune Engraftment Platform is made available by Taconic under license from the Wisconsin Alumni Research Foundation.